3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Keratosis, Actinic
5
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring NTRK Fusion
1
Small Cell Lung Carcinoma
1
Seizures
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Leukemia
1
Lennox Gastaut Syndrome
1
Head and Neck Neoplasms
1
Epilepsies, Myoclonic
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Anemia
1
Advanced Solid Tumors
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
51
Nivolumab
27
Gemcitabine
23
atezolizumab
19
Cisplatin
18
Carboplatin
18
enfortumab vedotin
15
avelumab
15
Mitomycin
14
Docetaxel
8
Ipilimumab
7
Paclitaxel
6
Injections
5
Cyclophosphamide
5
vinflunine
4
toripalimab
4
tislelizumab
4
lenvatinib
4
fludarabine
4
epacadostat
4
Pemetrexed
4
130-nm albumin-bound paclitaxel
4
sacituzumab govitecan
3
disitamab vedotin
3
Rogaratinib
3
Interleukin-2
3
ALT-803
3
vofatamab
2
valrubicin
2
rucaparib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Transitional Cell
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled